G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-213-9835
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees84
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions
What is G1 Therapeutics' stock symbol?
G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."
How were G1 Therapeutics' earnings last quarter?
G1 Therapeutics Inc (NASDAQ:GTHX) released its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.82) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.73) by $0.09. View G1 Therapeutics' Earnings History.
When is G1 Therapeutics' next earnings date?
What price target have analysts set for GTHX?
8 brokers have issued 1-year price targets for G1 Therapeutics' shares. Their forecasts range from $45.00 to $80.00. On average, they expect G1 Therapeutics' stock price to reach $66.6667 in the next year. This suggests a possible upside of 78.4% from the stock's current price. View Analyst Price Targets for G1 Therapeutics.
What is the consensus analysts' recommendation for G1 Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for G1 Therapeutics.
Has G1 Therapeutics been receiving favorable news coverage?
News stories about GTHX stock have been trending somewhat positive on Tuesday, InfoTrie reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. G1 Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for G1 Therapeutics.
Are investors shorting G1 Therapeutics?
G1 Therapeutics saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 3,926,300 shares, an increase of 5.1% from the June 30th total of 3,735,200 shares. Based on an average daily volume of 475,200 shares, the short-interest ratio is presently 8.3 days. Currently, 15.1% of the shares of the stock are short sold. View G1 Therapeutics' Current Options Chain.
Who are some of G1 Therapeutics' key competitors?
Some companies that are related to G1 Therapeutics include Amarin (AMRN), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC), FibroGen (FGEN), Allakos (ALLK), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE), Alkermes (ALKS), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR) and Arrowhead Pharmaceuticals (ARWR).
What other stocks do shareholders of G1 Therapeutics own?
Who are G1 Therapeutics' key executives?
G1 Therapeutics' management team includes the folowing people:
- Dr. Mark A. Velleca, CEO, Pres & Director (Age 55)
- Mr. James Stillman Hanson, Gen. Counsel (Age 47)
- Mr. Terry L. Murdock, Sr. VP of Devel. Operations (Age 59)
- Mr. John Demaree, Chief Commercial Officer (Age 52)
- Ms. Jennifer K. Moses, Chief Financial Officer (Age 44)
When did G1 Therapeutics IPO?
(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.
Who are G1 Therapeutics' major shareholders?
G1 Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.58%), Vanguard Group Inc. (5.27%), JPMorgan Chase & Co. (3.81%), Price T Rowe Associates Inc. MD (3.80%), Northern Trust Corp (0.81%) and Bank of America Corp DE (0.80%). Company insiders that own G1 Therapeutics stock include Barclay A Phillips, Clay Thorp, Cynthia Schwalm, Fredric N Eshelman, James S Hanson, Jay Strum, Jennifer K Moses, John Demaree, Mark A Velleca, Medimmune Ventures, Inc, Rajesh Malik, Seth Rudnick and Terry L Murdock. View Institutional Ownership Trends for G1 Therapeutics.
Which major investors are selling G1 Therapeutics stock?
GTHX stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Morgan Stanley, Citadel Advisors LLC, Bank of America Corp DE, Price T Rowe Associates Inc. MD, Invesco Ltd., Cubist Systematic Strategies LLC and SG Americas Securities LLC. Company insiders that have sold G1 Therapeutics company stock in the last year include Barclay A Phillips, Jay Strum, Jennifer K Moses, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View Insider Buying and Selling for G1 Therapeutics.
Which major investors are buying G1 Therapeutics stock?
GTHX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Tang Capital Management LLC, Nuveen Asset Management LLC, UBS Asset Management Americas Inc., Marshall Wace LLP, Vanguard Group Inc. and Rhenman & Partners Asset Management AB. Company insiders that have bought G1 Therapeutics stock in the last two years include Cynthia Schwalm, Fredric N Eshelman, James S Hanson and John Demaree. View Insider Buying and Selling for G1 Therapeutics.
How do I buy shares of G1 Therapeutics?
Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is G1 Therapeutics' stock price today?
One share of GTHX stock can currently be purchased for approximately $37.36.
How big of a company is G1 Therapeutics?
G1 Therapeutics has a market capitalization of $1.40 billion. The company earns $-85,290,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. G1 Therapeutics employs 84 workers across the globe.View Additional Information About G1 Therapeutics.
What is G1 Therapeutics' official website?
How can I contact G1 Therapeutics?
G1 Therapeutics' mailing address is 79 T.W. Alexander Drive 4501 Research Commons Suite 100, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835.
MarketBeat Community Rating for G1 Therapeutics (NASDAQ GTHX)
MarketBeat's community ratings are surveys of what our community members think about G1 Therapeutics and other stocks. Vote "Outperform" if you believe GTHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
